1. Home
  2. KLRS vs NRT Comparison

KLRS vs NRT Comparison

Compare KLRS & NRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KLRS
  • NRT
  • Stock Information
  • Founded
  • KLRS 2019
  • NRT 1975
  • Country
  • KLRS United States
  • NRT United States
  • Employees
  • KLRS N/A
  • NRT N/A
  • Industry
  • KLRS Biotechnology: Biological Products (No Diagnostic Substances)
  • NRT Oil & Gas Production
  • Sector
  • KLRS Health Care
  • NRT Energy
  • Exchange
  • KLRS Nasdaq
  • NRT Nasdaq
  • Market Cap
  • KLRS 46.0M
  • NRT 50.9M
  • IPO Year
  • KLRS N/A
  • NRT N/A
  • Fundamental
  • Price
  • KLRS $4.78
  • NRT $6.58
  • Analyst Decision
  • KLRS Strong Buy
  • NRT
  • Analyst Count
  • KLRS 3
  • NRT 0
  • Target Price
  • KLRS $21.50
  • NRT N/A
  • AVG Volume (30 Days)
  • KLRS 107.9K
  • NRT 48.7K
  • Earning Date
  • KLRS 11-13-2025
  • NRT 08-29-2025
  • Dividend Yield
  • KLRS N/A
  • NRT 7.28%
  • EPS Growth
  • KLRS N/A
  • NRT 24.05
  • EPS
  • KLRS N/A
  • NRT 0.59
  • Revenue
  • KLRS N/A
  • NRT $6,184,173.00
  • Revenue This Year
  • KLRS N/A
  • NRT N/A
  • Revenue Next Year
  • KLRS N/A
  • NRT N/A
  • P/E Ratio
  • KLRS N/A
  • NRT $10.89
  • Revenue Growth
  • KLRS N/A
  • NRT 18.55
  • 52 Week Low
  • KLRS $2.14
  • NRT $3.88
  • 52 Week High
  • KLRS $23.69
  • NRT $6.63
  • Technical
  • Relative Strength Index (RSI)
  • KLRS 47.17
  • NRT 70.73
  • Support Level
  • KLRS $4.67
  • NRT $5.95
  • Resistance Level
  • KLRS $5.10
  • NRT $6.45
  • Average True Range (ATR)
  • KLRS 0.41
  • NRT 0.26
  • MACD
  • KLRS -0.03
  • NRT 0.09
  • Stochastic Oscillator
  • KLRS 39.41
  • NRT 100.00

About KLRS Kalaris Therapeutics Inc. Common Stock

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

About NRT North European Oil Royality Trust

North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.

Share on Social Networks: